Thank you, John. Good afternoon, everyone, and thank you for joining us. I am also joined today by Jeff Gonzales, our Chief Financial Officer; Tae-Sik Yoon, our Chief Operating Officer; as well as other members of the management and Investor Relations team. During the second quarter, we continued to execute on our strategic objectives. We maintained a strong balance sheet, which has driven our progress addressing our risk-rated 4 and 5 loans and further reducing our office loans in the quarter. Importantly, the portfolio no longer includes loans collateralized by properties that are primarily used for life sciences. Given the progress we have made in narrowing the range of potential outcomes in our portfolio and having achieved our target balance sheet objective, we have begun investing in new and attractive loans. As we look forward, we expect origination activity to increase as we collect repayments and further address our risk-rated 4 and 5 loans and reduce our office loan holdings. Let me now walk you through the details of the quarter and lay the foundation for how we see these activities unfolding in order to drive higher levels of distributable earnings and dividend coverage. During the second quarter, we reduced our office loans to $524 million, a decrease of 10% quarter-over-quarter and a decrease of 30% year-over-year. This decrease was driven by repayments, active asset management and the decision to accelerate resolutions. Across office loans, including our rated 5 office loan, we saw improved leasing fundamentals and broadly speaking, more positive capital markets around the sector, which may also impact the rate of resolutions. During the second quarter, we exited a $51 million office life sciences loan and took a $33 million realized loss, which was in excess of the prior quarter CECL reserve. While we don't take any loss lightly, we believe the resolution of this loan creates greater stability in our portfolio. Reductions in federal funding for life science research led to further erosions in tenant demand and further elevated the supply-demand imbalance for life science properties. By exiting this loan, we removed significant unfunded commitments in the portfolio. The exit of this loan contributed to the 50% decrease in future funding commitments from $73 million in 1Q 2025 to $36.5 million as of June 30, 2025. We believe utilizing the strength of our balance sheet to exit the loan created greater certainty around our portfolio and allows us to get back to growth more quickly. We see this as an important advancement for the company as there are no remaining loans in the portfolio collateralized with properties that are primarily used for life sciences. We also changed the risk rating on an $81 million senior loan collateralized by an office property in Arizona to a risk rated 4 loan from a risk rating of 3. While occupancy increased at this property during the quarter and the sponsor has historically supported the asset, the lease- up business plan is taking longer than expected and with maturity coming up in October, discussions regarding an extension or modification with the sponsor are taking place. Let me now shift to our overall risk rated 4 and 5 loans. As of June 30, 2025, we had 1 risk-rated 5 loan and 4 risk-rated 4 loans, maintaining the same number of risk-rated 4 and 5 loans as we held last quarter. Notably, 2 of the 5 risk-rated 4 and 5 loans comprised 75% of the outstanding principal balance. The first of these 2 loans is our risk-rated 5 Chicago office loan with a carrying value of $146 million. Occupancy at this property has stabilized and remains above 90% with a weighted average lease term of more than 8 years. Post quarter end, the positive momentum at the property continued as a significant tenant amended and extended its lease, resulting in a $3 million payment to our borrower upon which the borrower applied these proceeds to reduce the principal balance of the loan. While we continue to see positive momentum towards the business plan, we note that challenges remain in the office sector with respect to the depth of investor demand, financing availability and thus valuations for office properties. The second of the 2 largest risk-rated 4 and 5 loans is our risk-rated 4 Brooklyn, New York residential condominium loan with a carrying value of $113 million. This property continues to hit development milestones on budget with nearly all of the remaining necessary materials to complete construction procured, which mitigates supply chain and known tariff risks. Subsequent to quarter end, the soft marketing launch began at the property, while the formal marketing and sales process is targeted to begin by 4Q 2025. Beyond these areas of focus in our loan portfolio, our risk-rated 1 to 3 loans, which are primarily collateralized by multifamily, industrial and self-storage properties continue to perform well with strong overall execution of business plans. Specifically, during the second quarter, we upgraded a risk-rated 3 $56 million loan collateralized by a hotel property to a risk rated 2 loan based on positively trending occupancy and operating cash flow levels. Beyond this positive risk rating upgrade, we believe the overall loan portfolio is much improved over recent quarters. Further, our balance sheet is positioned to both drive additional resolutions as well as invest our capital in new loans. To this end, following the end of the second quarter, we successfully executed our first investment commitments of the year. We closed 4 senior loans totaling $43 million in loan commitments collateralized by self-storage properties. While this marks our initial deployment into new loans in 2025, the overall Ares debt business has remained actively engaged in the real estate market with a strong and growing pipeline of opportunities. In the past 12 months, the team has originated over $6 billion of new investment commitments, primarily focused on mixed-use industrial and multifamily assets. Supported by the scale and reach of the broader Ares real estate platform, we expect origination activities to build in the third quarter and in future periods. While it is hard to predict timing, over the next 12 months, we expect the portfolio to be equal to or larger than it was as of 2Q 2025. From an earnings standpoint, we recognize that 2Q 2025 distributable earnings, excluding losses of $0.09 per share is below our dividend level of $0.15 per share. However, we remain confident that our earnings potential is in excess of the current dividend level. Our confidence in our earnings potential is derived from a number of levers that we can pull to enhance earnings, including the resolutions of our higher risk-weighted assets, redeploying our additional capital and making new loans. Looking ahead, we recognize that results may be uneven quarter-to-quarter, but our strategy remains clear, our execution purposeful and our outlook optimistic. Through our deliberate actions, we remain focused on accelerating resolutions on our higher-risk assets while not jeopardizing the integrity and strength of our balance sheet as we seek to clarify and demonstrate book value as quickly as possible. Ultimately, these actions and our return to investing in today's attractive environment should collectively begin to methodically rebuild our earnings in future periods. And with that, I'll turn the call over to Jeff, who will provide more details on our second quarter results.